Compounds > quinazolines
Page last updated: 2024-08-21

quinazolines and mk 2206

quinazolines has been researched along with mk 2206 in 15 studies

Research

Studies (15)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's14 (93.33)24.3611
2020's1 (6.67)2.80

Authors

AuthorsStudies
Hatch, H; Hirai, H; Kotani, H; Majumder, PK; Miyama, K; Nakatsuru, Y; Pan, BS; Sootome, H; Taguchi, S; Tsujioka, K; Ueno, Y1
Cheng, Y; Huber-Keener, KJ; Keihack, H; Liao, J; Liu, X; Ren, X; Rubin, E; Yan, L; Yang, JM; Zhang, L; Zhang, Y; Zhou, L1
Brown, S; Cosulich, SC; Crafter, C; Davies, BR; Dudley, P; Fairley, G; Faulder, P; Fillery, S; Greenwood, H; Hawkins, J; James, M; Johnson, K; Kettle, JG; Lane, CD; Pass, M; Pink, JH; Plant, H1
Goldberg, GL; Hazan, R; Horwitz, SB; Hou, JY; McDaid, HM; Rodriguez-Gabin, A; Samaraweera, L; Samaweera, L1
Biondo, A; Cassier, PA; Chen, E; de Bono, JS; Minton, S; Molife, LR; Papadopoulos, KP; Patnaik, A; Siu, LL; Sullivan, DM; Tetteh, E; Tolcher, AW; Vitfell-Rasmussen, J; Yan, L; Zernhelt, AM1
Baselga, J; Chandarlapaty, S; de Stanchina, E; Huang, X; Jiang, X; Liu, N; Monian, P; Qin, AC; Rodrik-Outmezguine, V; Rosen, N; Schneider, C; Toy, W; Will, M; Yao, Z1
Bokobza, SM; Devery, AM; Jiang, Y; Ryan, AJ; Weber, AM1
Schnellmann, RG; Smith, JA; Stallons, LJ1
Ariff, MA; Mathivanan, P; Parker, R; Rudra, T; Taub, M1
Chinn, DC; Gandara, DR; Holland, WS; Lara, PN; Mack, PC1
Bokobza, SM; Devery, AM; Jiang, Y; Ryan, AJ; Wadekar, R; Weber, AM1
Bell, MC; Burkard, ME; Eickhoff, J; Flynn, C; Kolesar, JM; Liu, G; Rampurwala, M; Tevaarwerk, AJ; Wisinski, KB1
Kwak, SJ; Seong, YS; Yi, YW; You, KS1
Bode, A; Grubbs, CJ; Juliana, MM; Lubet, RA; Moeinpour, F; Steele, VE1
Anderman, MF; Bhargava, D; Boccuzzi, L; de Miguel, FJ; Doroshow, JH; Durkin, ME; Lowy, DR; Papageorge, AG; Politi, K; Qian, X; Tripathi, BK; Walters, KJ; Wang, D1

Trials

2 trial(s) available for quinazolines and mk 2206

ArticleYear
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.
    Journal of hematology & oncology, 2014, Jan-03, Volume: 7

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Docetaxel; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Exanthema; Fatigue; Febrile Neutropenia; Female; Heterocyclic Compounds, 3-Ring; Humans; Male; Middle Aged; Nausea; Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-akt; Quinazolines; Stomatitis; Taxoids; Tinnitus; Treatment Outcome; Young Adult

2014
Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, 06-01, Volume: 22, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Breast Neoplasms, Male; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heterocyclic Compounds, 3-Ring; Humans; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines; Receptor, ErbB-2; Treatment Outcome; Young Adult

2016

Other Studies

13 other study(ies) available for quinazolines and mk 2206

ArticleYear
MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:7

    Topics: Allosteric Regulation; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Heterocyclic Compounds, 3-Ring; Humans; Lapatinib; Lung Neoplasms; Mice; Molecular Structure; Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Xenograft Model Antitumor Assays

2010
MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis.
    Molecular cancer therapeutics, 2012, Volume: 11, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Bcl-2-Like Protein 11; Beclin-1; Brain Neoplasms; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Gefitinib; Glioma; Heterocyclic Compounds, 3-Ring; Humans; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Microtubule-Associated Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; RNA Interference; RNA, Small Interfering

2012
Diverse heterocyclic scaffolds as allosteric inhibitors of AKT.
    Journal of medicinal chemistry, 2012, Feb-09, Volume: 55, Issue:3

    Topics: Allosteric Regulation; Animals; Biological Availability; Biomarkers; Cell Line, Tumor; Drug Screening Assays, Antitumor; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Mice; Mice, Nude; Models, Molecular; Neoplasm Transplantation; Proto-Oncogene Proteins c-akt; Pyrazines; Pyrazoles; Pyridazines; Pyridines; Quinazolines; Rats; Structure-Activity Relationship; Transplantation, Heterologous

2012
Exploiting MEK inhibitor-mediated activation of ERĪ± for therapeutic intervention in ER-positive ovarian carcinoma.
    PloS one, 2013, Volume: 8, Issue:2

    Topics: Animals; Antineoplastic Agents, Hormonal; Benzamides; Carcinoma; Cell Line, Tumor; Diphenylamine; Estradiol; Estrogen Receptor alpha; Extracellular Signal-Regulated MAP Kinases; Feedback, Physiological; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; Lapatinib; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Ovarian Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays

2013
Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling.
    Cancer discovery, 2014, Volume: 4, Issue:3

    Topics: Apoptosis; Cell Line, Tumor; Heterocyclic Compounds, 3-Ring; Humans; Lapatinib; MAP Kinase Signaling System; MCF-7 Cells; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines

2014
Combining AKT inhibition with chloroquine and gefitinib prevents compensatory autophagy and induces cell death in EGFR mutated NSCLC cells.
    Oncotarget, 2014, Jul-15, Volume: 5, Issue:13

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chloroquine; Drug Synergism; ErbB Receptors; Female; Gefitinib; Heterocyclic Compounds, 3-Ring; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Mutation; Proto-Oncogene Proteins c-akt; Quinazolines; RNA Interference; Xenograft Model Antitumor Assays

2014
Renal cortical hexokinase and pentose phosphate pathway activation through the EGFR/Akt signaling pathway in endotoxin-induced acute kidney injury.
    American journal of physiology. Renal physiology, 2014, Aug-15, Volume: 307, Issue:4

    Topics: Acute Kidney Injury; Animals; Enzyme Activation; ErbB Receptors; Gefitinib; Glucosephosphate Dehydrogenase; Glycolysis; Heterocyclic Compounds, 3-Ring; Hexokinase; Kidney Cortex; Lipopolysaccharides; Male; Mice; Pentose Phosphate Pathway; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines

2014
Antagonism of the prostaglandin E2 EP1 receptor in MDCK cells increases growth through activation of Akt and the epidermal growth factor receptor.
    American journal of physiology. Renal physiology, 2014, Sep-01, Volume: 307, Issue:5

    Topics: Animals; Bridged Bicyclo Compounds; Caproates; Cell Proliferation; Dogs; ErbB Receptors; Heterocyclic Compounds, 3-Ring; Hydrazines; Ibuprofen; Kidney; Madin Darby Canine Kidney Cells; Oxazepines; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Prostaglandin E, EP1 Subtype; Receptors, Prostaglandin E, EP2 Subtype; Receptors, Prostaglandin E, EP4 Subtype; Signal Transduction; Tyrphostins

2014
Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines.
    Journal of cancer research and clinical oncology, 2015, Volume: 141, Issue:4

    Topics: Apoptosis; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diphenylamine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Hepatocyte Growth Factor; Heterocyclic Compounds, 3-Ring; Humans; Immunoblotting; Lung Neoplasms; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; ras Proteins

2015
Vascular endothelial growth factor directly stimulates tumour cell proliferation in non-small cell lung cancer.
    International journal of oncology, 2015, Volume: 47, Issue:3

    Topics: Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2

2015
Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells.
    International journal of oncology, 2018, Volume: 52, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Female; Gefitinib; Gene Knockdown Techniques; Heterocyclic Compounds, 3-Ring; Humans; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Regulatory-Associated Protein of mTOR; Ribosomal Protein S6; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases; Triple Negative Breast Neoplasms

2018
Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKt inhibitor MK2206 in mammary cancer models.
    Oncology reports, 2018, Volume: 40, Issue:3

    Topics: Animals; Disease Models, Animal; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Heterocyclic Compounds, 3-Ring; Lapatinib; Male; Mammary Neoplasms, Experimental; Mice; Mice, Knockout; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Sprague-Dawley; Triazoles

2018
Inhibition of cytoplasmic EZH2 induces antitumor activity through stabilization of the DLC1 tumor suppressor protein.
    Nature communications, 2021, 12-03, Volume: 12, Issue:1

    Topics: Animals; Antineoplastic Agents; Benzodioxoles; Boron Compounds; Cell Line, Tumor; Enhancer of Zeste Homolog 2 Protein; Gene Knockdown Techniques; Gene Knockout Techniques; Glycine; GTPase-Activating Proteins; HEK293 Cells; Heterocyclic Compounds, 3-Ring; Humans; Lung Neoplasms; Mice; Mutagenesis, Site-Directed; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein Stability; Proto-Oncogene Proteins p21(ras); Quinazolines; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays

2021